LA
BMY icon

Linden Advisors’s Bristol-Myers Squibb BMY Stock Holding History

Linden Advisors’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-100,000
Closed -$5.53M – 129
2018
Q2 		$5.53M Buy
+100,000
New +$5.4M 0.17% 83
2015
Q2 		– Sell
-185,546
Closed -$12M – 67
2015
Q1 		$12M Buy
+185,546
New +$11.6M 1.95% 13

Other funds holding BMY

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Linden Advisors's BMY Position: Q1 2019 in Review

Linden Advisors sold out of Bristol-Myers Squibb (BMY) in Q1 2019, closing a stake of 431,000 shares — an estimated $22.4M sold.

Linden Advisors first reported a position in BMY in Q2 2018 and held it in 2 quarters. The position peaked at $22.4M in Q4 2018. 1,813 funds tracked by Wall St. Rank hold BMY as of Q1 2019.

  • Linden Advisors reported no remaining Bristol-Myers Squibb position as of Q1 2019 after selling out during the quarter.
  • Linden Advisors sold 431,000 Bristol-Myers Squibb shares in Q1 2019, an estimated $22.4M.
  • Linden Advisors first reported a position in Bristol-Myers Squibb in Q2 2018 and held it in 2 quarters.
  • Linden Advisors's Bristol-Myers Squibb position peaked at $22.4M in Q4 2018.
  • 1,813 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2019.

Based on Linden Advisors's 13F filing for Q1 2019, filed 15 May 2019.